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blockers, provided that the expected benefit to
treatment of the inflammatory disease is signifi-
cant. To our knowledge, this is the first study to
describe the long-term surveillance of patients
who developed TB while being treated with
TNF-a blocker therapy, and who then resumed
TNF-a treatment after being treated successfully
for TB. The data suggest that TB is not a
contraindication to recommencing anti-TNF-a
therapy if this would be beneficial for the under-
lying inflammatory disease.
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ABSTRACT
The decreasing prevalence of anti-Toxoplasma
antibodies in Europe has re-opened the question
of the appropriateness of serological screening
during pregnancy. A study of 3426 pregnant
women, resident in the Legnano area of Italy,
revealed that the IgG seroprevalence according to
ELISA was 21.5%, and that of IgM according to
ELISA and enzyme-linked fluorescent assay was
1.2% and 0.9%, respectively. The incidence of
infection, estimated on the basis of IgG avidity,
was 0.9%. These results confirm a decrease in the
prevalence of IgG, but indicate a high incidence of
infection, thus suggesting that screening for anti-
Toxoplasma antibodies during pregnancy should
be maintained.
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Screening tests for pregnant and pre-pregnant
women have been developed to prevent congen-
ital Toxoplasma gondii infection. These tests are
applied in various ways in France, Belgium,
Switzerland and Austria [1,2], but are not recom-
mended for routine use in the UK, The Nether-
lands or Norway [3,4]. In Italy, serological tests
for toxoplasmosis are performed as a routine
check during pregnancy. However, the decreas-
ing incidence of Toxoplasma infection in Europe
[5,6] has changed the epidemiological picture and
re-opened the debate concerning the appropriate-
ness of serological screening during pregnancy.
This has raised the question of how to calculate
the true incidence of this infection. Some of the
proposed mathematical models use data concern-
ing the seroprevalence of IgG- and IgM-specific
antibodies [7]. In particular, IgM antibodies seem
to be useful for detecting acute or recent infec-
tions; however, their early disappearance or
persistence over time limits their significance [8],
thus making it important to assess the avidity of
anti-Toxoplasma IgG antibodies. A high level of
IgG avidity usually excludes an infection during
the previous 3–5 months [9,10], so that, in the
absence of other clinical data, high titres of IgM
without IgG may indicate an acute infection,
while the presence of IgM and IgG with low or
borderline IgG avidity could indicate recent
infection. Thus, measuring avidity could provide
more useful data for calculating incidence. The
aim of the present study was to investigate the
prevalence and incidence of Toxoplasma infection
among pregnant women resident in the area of
Legnano (Milan, Italy) in order to evaluate the
appropriateness of maintaining Toxoplasma
screening during pregnancy.
In 2004 and 2005, 3426 pregnant women (aged
15–44 years) were referred to the Microbiology
Unit of Legnano Hospital for serological screen-
ing; 45.2% were in the first trimester of preg-
nancy, 29.3% were in the second, and 25.5% were
in the third.
IgG and IgM anti-Toxoplasma antibodies were
detected using ELISAs (ETI-TOXOK-G-PLUS and
ETI-TOXOK-M-reverse-PLUS; DiaSorin, Saluggia,
Italy). The IgG cut-off value was 15 IU ⁄mL; for
IgM, samples with an absorbance at least as great
as the value for the ‘cut-off control’ contained in
the kit were considered to be positive. The IgM-
positive samples were also tested using an
enzyme-linked fluorescent assay (ELFA) (VIDAS
Toxo IgM; bioMe´rieux, Marcy l’Etoile, France),
and were considered to be positive when the
index was ‡0.65, and as borderline when it was
between 0.55 and 0.64. IgG anti-Toxoplasma avid-
ity (VIDAS Toxo IgG Avidity; bioMe´rieux) was
assessed for the ELISA IgM-positive samples, and
was classified as low if the index was <0.2,
borderline if it was ‡0.2 to <0.3, and high if
it was ‡0.3. Samples that were rheumatoid
factor-positive (Arthri-Slidex; bioMe´rieux) were
not included in the analysis.
The incidence of toxoplasmosis was calculated
by adapting Janssen’s mathematical model for
calculating the incidence of human immunodefi-
ciency virus infections [11]:
Idt ¼ ðndt=NÞð365=TÞð100Þ
where Idt is incidence, ndt is the number of
individuals with low or borderline avidity, N is
the number of IgG-negative individuals plus
individuals with low or borderline avidity, and T
is the estimated mean number of days of low or
borderline avidity (=120) [10].
In total, 737 (21.5%) of the 3426 pregnant
women were positive for IgG, and 42 (1.2%) were
positive for IgM anti-Toxoplasma antibodies
according to ELISA (Table 1); 31 (73.8%) of the
42 IgM-positive samples were also positive or
borderline according to ELFA.
Avidity was measured in 37 samples, and was
low or borderline in eight (26.7%) of 30 ELFA
IgM-positive or borderline samples from five
women in the first, one in the second and two in
the third trimester, and in two (28.6%) of seven
ELFA IgM-negative samples, both from women in
the first trimester (Table 2). It was not possible to
investigate whether these were women with
persistently low IgG avidity, because they could
not be followed-up (these women were not
Table 1. Prevalence of IgG anti-Toxoplasma antibodies
(ELISA), IgM (ELISA and ELFA), and IgG avidity and
incidence in 3426 pregnant women during 2004–2005
Pregnant women
No. % 95% CI
ELISA IgG-positive 737 21.5 20.13–22.89
ELISA IgM-positive 42 1.2 0.86–1.60
ELFA IgM-positive 31 0.9 0.58–1.22
Low or borderline IgG avidity 10 0.3 0.11–0.47
Incidence 0.9 0.58–1.22
ELFA, enzyme-linked fluorescent assay.
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considered in the incidence calculation). IgG
avidity was not measured in five subjects because
they were IgG-negative. Each of these subjects
was weakly IgM-positive according to ELISA (the
ratio of sample absorbance to the ‘cut-off control’
absorbance was between 1 and 1.75). The women
who could be followed-up (all ELFA IgM-nega-
tive) showed the disappearance of ELISA IgM
after 2–7 months, but IgG was not detected in any
of these cases. Patient records documented the
presence of IgM 4–7 years previously for four
subjects with weakly positive IgM according to
ELISA and ELFA, and positive IgG and high IgG
avidity. The incidence estimated on the basis of
ELISA and ELFA IgM positivity with low or
borderline IgG avidity was 0.9% (Table 1).
Overall, the data indicated a prevalence of anti-
Toxoplasma IgG of 21.5% (95% CI 20.13–22.89),
which is similar to the figure reported in an Italian
study during 2000 [12], but is only about half the
prevalence recorded in Italy during the 1980s
[13,14]. The figure of 21.5% is also similar to that
reported in other European countries [5,6,15]. The
prevalence of anti-Toxoplasma IgM was 1.2%
(95% CI 0.86–1.60) according to ELISA, and
0.9% (95% CI 0.58–1.22) according to ELFA, but,
given the persistence of IgM over time, it is
difficult to use only IgM to estimate the incidence
of infection. Furthermore, non-specific phenom-
ena may make evaluation difficult; thus, in cases
with weak IgM positivity without IgG, the low
IgM titres remained constant or disappeared
without detection of IgG.
Considering low or borderline avidity in the
presence of IgM positivity according to both
ELISA and ELFA (actual presence of IgM) as the
means of identifying recent infections, the esti-
mated incidence (using Janssen’s mathematical
model for human immunodeficiency virus infec-
tion) was 0.9% (95% CI 0.58–1.22), which is
higher than incidences reported in northern
Europe [16,17], but similar to French data [18]
and lower than the incidence of 3.5% reported
recently for Italy [19]. However, these differences
may be related to the different mathematical
models used.
In conclusion, despite the decrease in toxoplas-
mosis, the incidence in the area studied is still one
of the highest in Europe (c. 9 ⁄ 1000 pregnant
women), which suggests that, at least in this area,
it is appropriate to maintain active screening for
toxoplasmosis during pregnancy.
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